GSK PLC (GSK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$49.89-1.93%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Intact: The reason to own it still holds.
GSK is growing cancer drugs with a $10.6 billion buyout. Sales are near $34 billion yearly. Earnings per share are about $5 next year. The company is profitable and stable.
Sales and earnings estimates have fallen recently. Growth could slow or stall. The cancer drug buyout may not pay off.
The market has no clear consensus on growth or fair value. Estimates show slight earnings decline. Our view expects stable growth from new cancer drugs.
Breaks if: EPS falls below $4.50 in FY27
Breaks if: Acquisition fails to contribute or is divested by FY27
Breaks if: YoY revenue growth falls below 3% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a moderate-risk play in the healthcare sector, which is currently experiencing a tailwind. The thesis is still in a nascent state, with insufficient recent financial performance to draw strong conclusions.
The market appears to have low expectations for GSK, as indicated by a muted price reaction. The current valuation reflects a cautious outlook, especially given the mixed signals from sector peers.
Fundamentals may remain stable in the near term, with a low probability of missing expectations. However, GSK's recent history includes a significant miss, which adds to the uncertainty.
The thesis hinges on the performance of sector bellwethers like LLY, JNJ, and ABBV. If these companies continue to perform well, they could provide momentum for GSK; conversely, any negative guidance from them could impact GSK adversely.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. GSK advanced its mRNA influenza vaccine into Phase III development, which is a significant milestone. However, Citi's view on the unproven Phase III pipeline poses challenges to long-term growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1-3 years, GSK's outlook is clouded by external factors and sector performance. Not investment advice.